The hypofunction of cholinergic neurons in the cholinergic basal forebrain nuclei and cerebral cortex impairs alzheimer’s patients’ cognitive functions. The cholinesterase inhibitor-rivastigmine, donepezil and galantamine- suppress the acetylcholinesterase activity of decomposing acetylcholine, reducing cholinergic damage and leading to some improvements in behavior, concentration, and social involvement, as well as cognitive functions. However, they have the drawback of side effect and drug resistance for long-term use. However, a glutamatergic N-methyl-D-aspartate receptor antagonist memantine, can also prevent amyloid-induced cholinergic neuron loss, and it expected to bring about good results if used in combination with a cholinesterase inhibitors.